다우존스 지수

같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

등록

홈
인베스팅
주식
미국
NASDAQ
SAB Biotherapeutics Inc (SABSW)
SAB Biotherapeutics Inc (SABSW) 뉴스

SABSW

SAB Biotherapeutics (SABSW)

SAB Biotherapeutics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:SABSW

1 2 3 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/21	20:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SABSW	SAB Biotherapeutics Inc
2024/05/21	06:45	GlobeNewswire Inc.	SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates	NASDAQ:SABSW	SAB Biotherapeutics Inc
2024/05/21	05:01	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:SABSW	SAB Biotherapeutics Inc
2024/05/06	20:15	GlobeNewswire Inc.	SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors	NASDAQ:SABSW	SAB Biotherapeutics Inc
2024/04/16	20:15	GlobeNewswire Inc.	SAB Biotherapeutics Provides SAB-142 Trial Update	NASDAQ:SABSW	SAB Biotherapeutics Inc
2024/04/08	20:15	GlobeNewswire Inc.	SAB Biotherapeutics to Present at INNODIA Annual Meeting	NASDAQ:SABSW	SAB Biotherapeutics Inc
2024/04/04	20:15	GlobeNewswire Inc.	SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference	NASDAQ:SABSW	SAB Biotherapeutics Inc
2024/03/29	20:15	GlobeNewswire Inc.	SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results	NASDAQ:SABSW	SAB Biotherapeutics Inc
2024/03/25	23:15	GlobeNewswire Inc.	SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment	NASDAQ:SABSW	SAB Biotherapeutics Inc
2024/02/23	22:00	GlobeNewswire Inc.	SAB Biotherapeutics to Present at the BIO CEO & Investor Conference	NASDAQ:SABSW	SAB Biotherapeutics Inc
2024/02/08	22:00	GlobeNewswire Inc.	SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	NASDAQ:SABSW	SAB Biotherapeutics Inc
2024/02/02	21:30	GlobeNewswire Inc.	SAB Biotherapeutics Announces Executive Leadership Change	NASDAQ:SABSW	SAB Biotherapeutics Inc
2024/01/24	07:58	GlobeNewswire Inc.	SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement	NASDAQ:SABSW	SAB Biotherapeutics Inc
2024/01/03	06:30	GlobeNewswire Inc.	SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split	NASDAQ:SABSW	SAB Biotherapeutics Inc
2023/11/29	21:30	GlobeNewswire Inc.	SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes	NASDAQ:SABSW	SAB Biotherapeutics Inc
2023/11/20	21:30	GlobeNewswire Inc.	SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors	NASDAQ:SABSW	SAB Biotherapeutics Inc
2023/11/14	21:30	GlobeNewswire Inc.	SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes	NASDAQ:SABSW	SAB Biotherapeutics Inc
2023/11/14	21:15	GlobeNewswire Inc.	SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates	NASDAQ:SABSW	SAB Biotherapeutics Inc
2023/11/09	21:30	GlobeNewswire Inc.	SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference	NASDAQ:SABSW	SAB Biotherapeutics Inc
2023/10/24	20:30	GlobeNewswire Inc.	SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer	NASDAQ:SABSW	SAB Biotherapeutics Inc
2023/10/19	20:30	GlobeNewswire Inc.	SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes	NASDAQ:SABSW	SAB Biotherapeutics Inc
2023/10/05	20:30	GlobeNewswire Inc.	SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors	NASDAQ:SABSW	SAB Biotherapeutics Inc
2023/10/02	20:30	GlobeNewswire Inc.	SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes	NASDAQ:SABSW	SAB Biotherapeutics Inc
2023/08/21	21:30	GlobeNewswire Inc.	SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results	NASDAQ:SABSW	SAB Biotherapeutics Inc
2023/06/21	21:30	GlobeNewswire Inc.	SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023	NASDAQ:SABSW	SAB Biotherapeutics Inc
2023/05/30	21:30	GlobeNewswire Inc.	SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention	NASDAQ:SABSW	SAB Biotherapeutics Inc
2023/05/19	21:30	GlobeNewswire Inc.	SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy Innovations	NASDAQ:SABSW	SAB Biotherapeutics Inc
2023/05/16	21:30	GlobeNewswire Inc.	SAB Biotherapeutics Provides Company Update for Q1 2023 Financial Results	NASDAQ:SABSW	SAB Biotherapeutics Inc
2023/05/12	21:30	GlobeNewswire Inc.	SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal Antibodies	NASDAQ:SABSW	SAB Biotherapeutics Inc
2023/05/09	21:30	GlobeNewswire Inc.	SAB Biotherapeutics Announces Progress on U.S. FDA’s Phased Review of Company’s Groundbreaking DiversitAb™ Platform	NASDAQ:SABSW	SAB Biotherapeutics Inc

검색 관련기사 보기:NASDAQ:SABSW

1 2 3 다음 >>

US Dollar vs Yen

Invesco QQQ Trust Series 1

JP Morgan Chase

BNP Paribas (QX)

Deutsche Telekom (QX)

Energy Select Sector SPDR

US Dollar vs Sterling

Financial Select Sector

Gold vs US Dollar

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관